Malawi, being the very first country to have rolled out the world’s first licensed malaria vaccine for children, has undoubtedly created a major breakthrough in the extensive field of immunization. As the World Health Organization (WHO) has marked World Malaria Day on April 25th, Malawi, a landlocked country in South-Eastern Africa, has come up with a pilot phase of the very first Malaria vaccine of Africa. Apart from Malawi, the WHO has also included Ghana and Kenya mainly because of soaring numbers of Malaria-affected patients and plummeting treatment facilities for this life-threatening epidemic.
This groundbreaking discovery is specifically aimed at vaccinating 360,000 children under two on Malawi, Ghana, and Kenya in Sub-Saharan Africa that witness 435,000 deaths every year globally owing to Malaria. Even though Malaria can take a serious toll on anyone regardless of age and gender, it’s the children under five years old whose lives could be at stake due to this ailment. It’s shocking to come to terms with the fact that at least 250,000 children are dying from Malaria in Africa every year! This vaccine, named as Mosquirix has certainly brought a ray of hope for the native civilians of Africa.
How Mosquirix Came into Being?
The RTS, S/ASO1 or Mosquirix was developed by GlaxoSmithKline, which is reckoned as a top-notch pharmaceutical giant in Britain. This innovation milestone was approved by the European Medicines Agency in the year 2015. In a previous trial, Mosquirix was found to be partly effective amongst children
Although the effectiveness of the vaccine is a tad limited, Padro Alonso, the Director of the Malaria Program of WHO is still extremely confident about what this vaccine could proffer in the future. In one of his recent conversations, he has said that similar vaccination program will take place in the forthcoming weeks in Ghana and Kenya, with an objective to protect legions of children each year across the three African countries.
A Quick Overview of Mosquirix
Known by its lab initials RTS,S/AS01 and labeled as Mosquirix is an injectable recombinant protein-based vaccine, which is capable of acting against P. falciparum, a highly prevalent Malaria strain across the African countries. The vaccine holds ample potential to prevent 4 in 10 cases of Malaria among the children, who received four doses over a period of 4 years. The WHO has embraces the pilot program by the Malawi Government.
Mosquirix has been through a number of brain-storming scientific trials that have proclaimed it a safe vaccination program. According to such trials, Mosquirix can minimize the risk of Malaria by 40 percent. As this vaccine is yet to beat many challenges and shatter plenty of obstacles, it ought to be supplemented by the conventional anti-Malaria tools like insecticide-treated bed nets. This apart, four successive doses should be administered on a specific timetable for it to spell its magic.
In a Nutshell
Despite having been able to hog the limelight due to its hitherto unexplored potential to combat Malaria, Mosquirix has still many miles to go to prove its efficacy. The vaccine has come into being very recently, and hence, it’s still considered to be in a cursory stage of development.
The invention of Mosquirix has certainly marked a historical moment, as it’s never been a cakewalk to design a vaccine against a parasite as opposed to a virus or bacteria. The stalled proliferation against Malaria definitely demands an array of new tools now. Midst a time when mosquitoes are increasingly becoming resistant to insecticides and funding for treating Malaria is getting stagnant, the arrival of such an earth-shattering discovery (read Mosquirix) has certainly brought a sigh of relief for the native Africans. It entailed more than 30 years for GSK to make this vaccine a reality at a hefty cost of around 1 billion dollars! GSK is now donating up to 10 million vaccine doses in its present vaccination initiatives. In order to raise a bigger and more secure fund for taking this vaccination program to another level, GSK is tying up with its top-tier partners.
Even though Mosquirix is gradually acceding to the crescendo of popularity, it could be a bit challenging to convince parents to bring their children for the repeated doses of a vaccine, which will just protect a child for a limited time-span. However, it’s anticipated that this Malaria vaccine will save legions of lives, even if it is just off the boat and yet to walk many miles to reach the crest of success.
Written by : Tania Ghosh have 4+ years of experience as a professional content writer. She holds a Master’s Degree in English Literature. With a mélange of a creative mind, an eye for perfection and ample experience in the field of digital content writing, she has capacitated herself to communicate through wordplay. As a senior content connoisseur, she has worked on composing a wide repertoire of write-ups including, articles, blogs, web contents, press releases, classified ads, social media contents, and the likes. She has had an exposure to compose contents on diverse domains such as Healthcare, Lifestyle, Fashion, Technology, Travel, Product Description, and the likes.